solid masses with moderate or rich vascularization. Cervical NENs appear as hypoechoic solid tumors, with irregular margins and highly vascularization and endometrial NENs are solid hypoechoic tumors with irregular margins.

IGCS20_1209

211 VULVAR AND VAGINAL METASTASIS OF SIGMOID ADENOCARCINOMA: A RARE LOCALIZATION

Y Fertani*, I Bouraoui, M Bouhani, R Chargui, F Saadallah, I Zemni, K Rahal. *Surgical Oncology of Salah Azaiez Institute, Tunisia*

10.1136/ijgc-2020-IGCS.182

Introduction Metastasis to genital tract are rare and usually secondary to breast and gastrointestinal malignancies.

Vulvar and vaginal metastasis from Colon cancer are extremely rare with few cases reported in the littérature.

Our case is unique because of simultaneous metastasis from sigmoid carcinoma to the vulva and vagina. It is to our knowledge the first case with this simultaneous localization of colorectal carcinoma.

Abstract 211 Figure 1

Case Report We present a case of 50-year-old woman with history of an adenocarcinoma of the sigmoid evolving since 2016 with liver metastasis. She underwent a sigmoidectomy without metastasis resection, followed by chemotherapy with folfox then LV5FU. After one year she presented with a vaginal bleeding associated to a vulvar mass.

Clinical exam showed an enlarging firm not well defined and bleeding mass of the left labia major infiltrating the underlying tissue. Gynecologic exam showed a rigid and irregular mass infiltrating vaginal wall.

The rest of the exam was normal. Tumors' markers were negative. MRI and Ct scan showed a liver progression and vulvar mass infiltrating the vagin.

Biopsy of the vaginal and vulvar masses concluded to a metastasis from the initial sigmoid tumor.

The multidisciplinary meeting agreed to pursue the treatment with folfiri chemotherapy.

Unfortunately, the patient passed away few months later.

Conclusion vulvar metastasis counts for 2 to 8% of vulvar tumours.

This case is unique because it reports a simultaneous localization to the vulva and vagina from colorectal carcinoma which is to our knowledge the first case in the literature.

IGCS20_1210

212 SINGLE-AGENT AMRUBICIN THERAPY FOR RECURRENT SMALL CELL NEUROENDOCRINE CERVICAL CARCINOMA

S Minobe*. *Hokkaido Cancer Center Gynecol, Japan*

10.1136/ijgc-2020-IGCS.183

Small cell neuroendocrine cervical cancer (SCNCC) is a highly aggressive tumor, and there is currently no standard treatment for recurrent SCNCC. We treated three patients with recurrent SCNCC who had received prior etoposide/cisplatin chemotherapy with single-agent amrubicin (35 mg/m², days 1–3). Partial response was achieved in one patient who had no signs of disease progression 14 months after commencing amrubicin. This patient received a total of 10 cycles of amrubicin every 3 weeks, with acceptable adverse effects. Amrubicin treatment was unsuccessful and was discontinued in the other two patients; one received a total of five cycles of amrubicin with acceptable adverse effect, but amrubicin was discontinued because of disease progression, and the other discontinued amrubicin after only two cycles because of grade 4 neutropenia/thrombocytopenia.

IGCS20_1212

214 NO SOCIOECONOMIC DIFFERENCES IN OVERALL SURVIVAL SEEN IN PATIENTS WITH ADVANCED OVARIAN CANCER WHERE PARITY OF ACCESS TO TREATMENT AND CYTOREDUCTIVE OUTCOMES CAN BE ACHIEVED

L Watson, T Hatfield, G Lavender, A Phillips*. *Derby Gynaecological Cancer Centre, University Hospitals of Derby and Burton NHS Foundation Trust, UK*

10.1136/ijgc-2020-IGCS.184

Introduction The impact on socioeconomic status on survival in advanced ovarian cancer (AOC) is controversial. Whilst previous epidemiological studies suggested no socioeconomic differences in survival in AOC, more recent studies found that less deprived patients may have longer overall survival (OS) due to a greater utilisation of treatment and better outcomes from those treatments.

The aim of this study was to investigate whether any socioeconomic differences were evident in patients treated at a cancer centre serving a well-defined population and what impact, if any, the implementation of a change in surgical paradigm had on this disparity.

Methods A retrospective review of 679 patients with Advanced Stage 3 and 4 Epithelial Ovarian, Tubal and Fallopian tube cancer (AOC) diagnosed between 6th January 2003 and 29th March 2019. All patients were classified by UK postcode using the Index Multiple Deprivation (IMD) into five groups. Data was collected on OS, treatment approach and cytoreductive outcomes.

Results No difference was seen in access to surgery or cytoreductive outcomes obtained by IMD group. Across the entire cohort no significant difference in OS was seen across the five groups. When comparing the patients before and after a change towards extensive surgery in 2014, again, no significant difference in OS was seen.

Conclusions Assuming parity of exposure to treatment and outcomes can be achieved, we witnessed no disparity in AOC survival by socioeconomic group. Improving access to and quality of care in all patients is likely to reduce any socioeconomic differences in survival.

IGCS20_1216

217 BREAST CANCER IN CAP BON: EPIDEMIOLOGICAL AND HISTO-PROGNOSTIC FEATURES

¹A Triki, ¹K Ben Hamida*, ¹Jebir, ¹M Ghalleb, ¹M Hadidane, ²H Bel Fekih, ¹H Makhoulouf, ¹H Touinsi. ¹Department of Surgery, Mohamed Taher Maamouri Hospital, Tunisia; ²Department of Medical Oncology, Mohamed Taher Maamouri Hospital, Tunisia

10.1136/ijgc-2020-IGCS.185

Introduction Breast cancer is the most common malignancy in women around the world. In the Cap Bon, the epidemiological features of breast cancer are unknown.

We aim to identify the epidemiological, clinical, and histological characteristics of breast cancer in the Cap Bon.

Methods A retrospective study of 130 patients diagnosed with breast cancer from January 2014 to December 2017 and treated in Mohamed Taher Maamouri Hospital of Nabeul, Tunisia.

Results Five patients (3.8%) were male. The average age was 55.7 years. The young women (≤ 35 years) represented 4.6%. Stage T2 was predominantly observed (48.8%). The tumors were classified as N1 in 54.2% of cases. Four patients (3%) had Metastasis. The infiltrating ductal carcinoma was the most common histological type (80%). The average histological size was 27.7 mm. The most common molecular subtype was Luminal B (48%). The nodes were

positive in 57.4% of cases. All the patients had breast surgery. It was conservative in 40% of cases. Radiotherapy was performed in 87.3% of cases. The chemotherapy was administered to 73.8% of patients. The trastuzumab was administered to 76.4% of the patients. Hormonotherapy was administered to 90.3% of patients. Overall survival and progression-free survival at 3 years were 90% and 73.2% respectively. Prognostic factors were the N stage and the lymph node involvement.

Conclusion The epidemiological characteristics of breast cancer in the Cap Bon present a number of similarities to the other regions of the country. However, it differs from the high frequency of pejorative histoprosthetic factors.

IGCS20_1218

218 ROLE OF FROZEN SECTION IN SURGICAL STAGING OF EARLY – STAGE ENDOMETRIAL CANCER: EXPERIENCE AT HOSPITAL SOTERO DEL RIO

E Pertossi*, M Urzúa, M Perez, O Puga, N Saez, J Retamales. Hospital Sótero del Río/ Pontificia Universidad Católica de Chile, Chile

10.1136/ijgc-2020-IGCS.186

Introduction EC has high incidence in Chile. Although most are diagnosed in early stages, some of them have ganglionic compromise at time of surgery. Taking in count morbidity associated with PPaLND, FS is determinant in staging.

Objective to assess the agreement rate between contemporary and definitive biopsy and how it affects our clinical conduct.

Methods retrospective analysis of clinical charts and pathology reports between 2005–2020 at Hospital Sotero del Río. Statistical analysis based on software R version 3.6.1.

Results 410 patients with early-stage EC and surgical treatment. Average age was 61 y-old (26–84), BMI 31 (17–56), 342 (83%) multiparous, most common comorbidities were hypertension and diabetes. We performed 282 (68.7%) FSs and 61 (22%) had a change in clinical conduct. Variables associated with it were histology, myometrial invasion and grade of differentiation ($p=0.003$ and $p<0.0001$ and 0.004 respectively). Histology and differentiation agreement between preoperative biopsy and definitive report was 76.2% (Kappa 0.372) and 64.6% (Kappa 0.457). Agreement for histology, grade of differentiation and myometrial penetration between FS and definitive report were 74.9% (Kappa 0.279) 76% (Kappa 0.588) and 84.9% (Kappa 0.692) respectively. 7 patients (1.7%) were upstaged and 16 (3.9%) did not. The reasons for not performing it were high risk histologies, extrauterine disease, intraoperative complications, unnoticed neoplasia in TH and high surgical risk. Definitive pathology reports were endometrioid in 81% (331), serous 9% (38), sarcoma 2.6% (11), hyperplasia 2.6% (11), clear cells 2.4% (10) and others 2.1% (9).

Conclusions FS is a determinant and feasible tool in clinical decisions respecting surgical staging.